Baicalein Anti-Tumor Effects on Choroidal Melanoma via PI3K/AKT/mTOR Pathway

Table 3 from a 2026 study by Lili Wu presents integrated analysis results on the flavonoid baicalein's mechanism against choroidal melanoma. The 9.5 KB Excel file contains findings from network pharmacology, transcriptomics, and experimental validation. It details targets, signaling pathways, and in vitro results from C918 and OCM-1 cell lines.

Use Cases

• Identify potential drug targets like PI3K/AKT/mTOR from network pharmacology analysis results.
• Analyze transcriptomic data on cell cycle, apoptosis, and migration-related protein expression changes.
• Validate molecular docking scores for baicalein binding to specific pathway targets.
• Correlate in vitro experimental results, such as proliferation inhibition and oxidative stress injury, with predicted pathway activity.
• Examine the effects of IGF-1 co-treatment on pathway phosphorylation levels and downstream protein activity.

Strengths

• Data integrates three methodologies: network pharmacology, transcriptomics, and wet-lab experimental verification.
• Findings are validated across two choroidal melanoma cell lines (C918, OCM-1) and an allograft tumor model.
• Dataset is openly licensed under CC-BY-4.0, facilitating reuse.

Limitations

• The dataset is very small at 9.5 KB, indicating limited scope, likely a single summary table.
• Specific row counts, column names, and raw experimental data values are not provided.
• Findings are specific to choroidal melanoma and two cell lines, limiting generalizability to other cancers.

Provenance

Source

Lili Wu, published on figshare.

Collection Method

Generated via integrated network pharmacology, transcriptomic analysis, molecular docking, and in vitro/vivo experimental validation.

Time Range

Study period not specified; publication date is 2026.

Freshness

Last updated in April 2026, representing recent research.